论文部分内容阅读
目的探讨双歧杆菌乳杆菌三联活菌片对肝硬化自发性腹膜炎(SBP)患者肠黏膜屏障功能的保护作用。方法选取乙肝后肝硬化SBP患者68例,随机分为观察组和对照组各34例。两组患者均予以保肝利尿、降血氨、降低门脉压、抗感染、补充白蛋白和营养支持等常规治疗。观察组患者加用双歧杆菌乳杆菌三联活菌片2.0 g/次,2次/d,连用2周。对照组患者除不使用双歧杆菌乳杆菌三联活菌片余治疗同观察组。观察两组患者治疗前后血清DAO和D-Lac水平的变化,并比较临床疗效。结果治疗2周后,两组患者血清DAO和D-Lac水平均较前明显下降(P<0.05或P<0.01),且观察组下降值明显大于对照组(P<0.05);同时观察组患者的临床总有效率(94.12%)明显高于对照组(73.53%)(χ2=5.31,P<0.05)。结论双歧杆菌乳杆菌三联活菌片辅助治疗肝硬化SBP患者具有较好疗效,具有良好肠黏膜屏障保护功能。
Objective To investigate the protective effect of Lactobacillus bifidum triple active viable tablet on intestinal mucosal barrier function in patients with cirrhosis spontaneous peritonitis (SBP). Methods Sixty-eight patients with post-hepatitis B cirrhosis SBP were randomly divided into observation group (34 cases) and control group (34 cases). Two groups of patients are to liver protection diuretic, hypothyroxine, reduce portal pressure, anti-infection, albumin and nutritional supplements and other routine treatment. Patients in the observation group were treated with Lactobacillus bifidum triple viable 2.0 g once daily for 2 weeks. Patients in the control group except for the use of bifidobacterium Lactobacillus triple viable tablets treatment with the observation group. The changes of serum DAO and D-Lac levels before and after treatment in both groups were observed, and the clinical efficacy was compared. Results After 2 weeks of treatment, the serum levels of DAO and D-Lac in both groups were significantly lower than those in the control group (P <0.05 or P <0.01), and the decrease in the observation group was significantly greater than that in the control group (P <0.05) The total clinical effective rate (94.12%) was significantly higher than that of the control group (73.53%) (χ2 = 5.31, P <0.05). Conclusion Lactobacillus bifidum triple viable bacterial tablet adjuvant treatment of cirrhotic patients with SBP has a good effect, with good intestinal barrier protection.